Hims & Hers has seen a significant surge in its stock prices, skyrocketing up to 40%, following the announcement of a partnership with Novo Nordisk to market the weight-loss drug Wegovy. The collaboration aims to enhance affordable access to the obesity medication through multiple telehealth platforms. This strategic move comes as Novo Nordisk expands its efforts to make Wegovy more accessible, joining forces with several telehealth firms in the U.S. Shares of Hims & Hers have experienced a powerful upswing, with analysts raising their price target as interest in the drug increases. The partnership marks a pivotal step for both companies in the telehealth weight-loss market.